ENDURONYL FORTE
LOE ApproachingNDAORALTABLET
Approved
Aug 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENDURONYL FORTE is an oral small-molecule tablet approved by Abbott in 1961. The mechanism of action and therapeutic indications are not publicly documented in available data. This product represents a legacy franchise with significant historical commercial presence.
LOE Approaching
LOE-stage products typically operate with reduced commercial investment and smaller field teams focused on legacy volume retention and managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ENDURONYL FORTE represents a legacy brand with minimal new job creation, reflecting its LOE trajectory. Roles on this product focus on volume management, customer retention, and managed decline rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on ENDURONYL FORTE at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.